Association of NRAS mutations and tertiary lymphoid structure formation with clinical outcomes of adjuvant PD-1 inhibitors for acral melanoma

Mo, Zeming; Liu, Jie; Zhang, Jinyan; Deng, Yaotiao; Xu, Miao; Jiang, Yu

doi:10.1016/j.intimp.2023.110973

Cited by 2 publications

(5 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After screening based on predetermined criteria, 13 studies were selected for further evaluation through abstract review in accordance with the inclusion criteria. Due to small sample sizes, the 4 studies ( 14 , 17 – 19 ), were only included in the systematic review. Therefore, this meta-analysis selected 9 studies ( 11 – 13 , 15 , 16 , 21 , 28 – 30 ) investigating the correlation between TLSs and clinical outcomes in cancer patients treated with immune checkpoint inhibitors.…”

Section: Resultsmentioning

confidence: 99%

“…In recent years, the role of TLSs in immunotherapy response to solid tumors has received extensive attention ( 11 – 19 , 21 , 28 – 31 ), with melanoma being the most commonly reported tumor ( 11 , 17 , 28 – 30 ). In general, the presence or a higher density of TLSs were predicting a significantly prolonged OS and PFS in cancer patients treated with ICIs.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Association between tertiary lymphoid structures and clinical outcomes in cancer patients treated with immune checkpoint inhibitors: an updated meta-analysis

Li,

Guo,

Gong

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

BackgroundAlthough numerous studies have reported the association between tertiary lymphoid structures (TLSs) and clinical outcomes in cancer patients treated with immune checkpoint inhibitors (ICIs), there remains a lack of a newer and more comprehensive meta-analysis. The main objective of this study is to explore prognostic biomarkers in immunotherapy-related patients, through analyzing the associations between tertiary lymphoid structures (TLSs) and clinical outcomes in cancer patients treated with ICIs, so as to investigate their prognostic value in cancer patients treated with ICIs.MethodsA comprehensive search was conducted until February 2024 across PubMed, Embase, Web of Science, and the Cochrane Library databases to identify relevant studies evaluating the association between tertiary lymphoid structures and clinical outcomes in cancer patients treated with ICIs. The clinical outcomes were overall survival (OS), progression‐free survival (PFS), and objective response rate (ORR).ResultsThirteen studies were incorporated in this meta-analysis, among which nine evaluated the prognostic value of TLSs. The results showed the high levels of TLSs predicted a significantly prolonged OS (pooled HR = 0.35, 95% CI: 0.24–0.53, p < 0.001) and PFS (pooled HR = 0.47, 95% CI: 0.31–0.72, p < 0.001), while lower ORR (pooled OR = 3.78, 95% CI: 2.26–6.33, p < 0.001) in cancer patients treated with ICIs.ConclusionOur results indicated that high levels of TLSs could predict a favorable prognosis for cancer patients treated with ICIs and have the potential to become a prognostic biomarker of immunotherapy-related patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Association between tertiary lymphoid structures and clinical outcomes in cancer patients treated with immune checkpoint inhibitors: an updated meta-analysis

Li,

Guo,

Gong

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…In China, a study explored the relationship between NRAS and tertiary lymphoid structures (TLS) in the adjuvant therapy involving anti‐PD‐1 antibodies for acral melanoma. It observed low efficacy of anti‐PD‐1 in the acral type with an NRAS mutation 26 . They reported that the efficacy of anti PD‐1 antibodies in the acral type with an NRAS mutation is low.…”

Section: Real World Evidence Relapse‐free Survival and Overall Survivalmentioning

confidence: 99%

“…Varied levels of TLS infiltration did not significantly impact patient survival. The authors concluded that adjuvant anti‐PD‐1 antibodies may not be suitable for treating acral melanoma with NRAS mutations 26 . This speculation is interesting, but as it is a study of a small number of cases, the interpretation should carefully be made.…”

Section: Real World Evidence Relapse‐free Survival and Overall Survivalmentioning

confidence: 99%

See 1 more Smart Citation

Deciphering the role of adjuvant therapy in melanoma and its actual benefits

Fukushima,

Miyashita,

Kimura

et al. 2024

The Journal of Dermatology

View full text Add to dashboard Cite

Numerous clinical trials have demonstrated a significant improvement in recurrence‐free survival among melanoma patients receiving high‐dose interferon‐α, immune checkpoint inhibitors (pembrolizumab, nivolumab), and BRAF/MEK inhibitors (dabrafenib‐trametinib). This study aimed to investigate whether these findings hold true in real‐world conditions for patients with stage III and IV melanoma. In particular, the study explores the efficacy and side effects of adjuvant therapies, focusing on anti‐PD‐1 antibodies and BRAF/MEK inhibitors. While clinical trials have shown comparable efficacy, differences in side‐effect profiles, especially the persistence of immune‐related adverse events with anti‐PD‐1 antibodies, highlight the need for careful consideration in adjuvant settings. In the absence of established biomarkers for guiding adjuvant therapy decisions, it becomes imperative to transparently communicate the advantages and disadvantages of drug administration to patients. The study also delved into the impact of melanoma subtype and BRAF mutation status on the effectiveness of adjuvant therapy, emphasizing the need for further investigation.

show abstract

Association of NRAS mutations and tertiary lymphoid structure formation with clinical outcomes of adjuvant PD-1 inhibitors for acral melanoma

Cited by 2 publications

References 42 publications

Association between tertiary lymphoid structures and clinical outcomes in cancer patients treated with immune checkpoint inhibitors: an updated meta-analysis

Association between tertiary lymphoid structures and clinical outcomes in cancer patients treated with immune checkpoint inhibitors: an updated meta-analysis

Deciphering the role of adjuvant therapy in melanoma and its actual benefits

Contact Info

Product

Resources

About